Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +52

Edwards Lifesciences wins FDA approval for PASCAL tricuspid repair - Mugglehead Investment Magazine

Drug approval AI-generated analysis

πŸ₯ Edwards Lifesciences received FDA approval for the PASCAL Precision device to treat severe symptomatic tricuspid regurgitation in patients failing medical therapy.

πŸ“ˆ The stock price increased by 0.84% to $89.00 on the NYSE immediately following the regulatory announcement.

πŸ”¬ Edwards plans to present one-year pivotal findings from the CLASP II TR study at the TCT cardiology meeting scheduled for late October.

πŸ‘₯ The new indication targets patients with severe leakage who are suitable for transcatheter edge-to-edge repair and face intermediate or greater surgical risk.

πŸ’Ό Edwards now offers a complete portfolio of transcatheter repair and replacement therapies for both mitral and tricuspid valves in the U.S.

πŸ“Š The CLASP II TR study involves an estimated enrollment of 1,270 patients across randomized and registry cohorts to assess long-term outcomes.

βš–οΈ The approval places Edwards' PASCAL device alongside Abbott Laboratories' TriClip system as a nonsurgical treatment option for tricuspid regurgitation.

Bullish Signals
  • Edwards Lifesciences secured FDA approval for a new indication of its PASCAL Precision device, expanding its structural heart portfolio to include severe symptomatic tricuspid regurgitation.
  • The company's stock price rose 0.84% to $89.00 on the NYSE following the positive regulatory news regarding the tricuspid valve therapy.
Full Analysis
Edwards Lifesciences (NYSE: EW) announced that the U.S. Food and Drug Administration has approved its PASCAL Precision device for a new indication in severe symptomatic tricuspid regurgitation. This approval covers patients with leakage who have not responded to optimal medical therapy and are at intermediate or greater surgical risk, marking a significant expansion of Edwards' structural heart portfolio. The company plans to present one-year pivotal results from the CLASP II TR study at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego. While the FDA approval was granted, the release did not include specific outcome figures, analyzed patient counts, or a separate launch date for the new tricuspid therapy in the United States. Edwards shares rose 0.84% to $89.00 following the news, reflecting investor interest in the broadened reach of its transcatheter repair capabilities. The company now offers both mitral and tricuspid transcatheter repair and replacement therapies, positioning itself alongside competitors like Abbott Laboratories' TriClip system, though no head-to-head comparison data was provided.